#WuXi Biologics #FTSE4Good #Green CRDMO

WuXi Biologics Retains FTSE4Good Recognition for Sixth Straight Year

WuXi Biologics, a prominent player in the realm of Contract Research, Development, and Manufacturing Organizations (CRDMO), has made headlines once again by being recognized in the FTSE4Good Index Series. This accolade marks the sixth consecutive year that the company has achieved this prestigious distinction. The acknowledgment serves as a testament to WuXi Biologics' consistent commitment to sustainability and demonstrates its capability to generate substantial value for global partners through its innovative Green CRDMO solutions.

The FTSE4Good Index Series, which was established by FTSE Russell and is now part of the London Stock Exchange Group, is designed to measure the performance of companies with robust Environmental, Social, and Governance (ESG) practices. This year, WuXi Biologics was proud to be ranked in the top 4% of the global healthcare sector for its ESG performance. The assessment took into account several vital areas, including corporate governance, ethics, labor standards, and proactive environmental management.

As a leader in sustainable CRDMO solutions for biologics, WuXi Biologics integrates sustainable practices across all aspects of its operations, management, technology, and supply chain systems. These efforts enable the company to enhance research and development (R&D) efficiency while significantly reducing the carbon footprint and lifecycle environmental impacts of its products. With increasing global pressures for sustainable procurement, WuXi Biologics is uniquely positioned to meet these rising demands.

Dr. Chris Chen, CEO of WuXi Biologics, expressed pride in the company’s achievements, stating, "Receiving the recognition of FTSE4Good for the sixth year in a row reflects our progress in aligning our business practice with high-standard ESG initiatives. We are dedicated to continuing this trajectory, integrating sustainability within our long-term growth strategy. Moving forward, our objective remains to enhance our Green CRDMO strategy, collaborating with global partners to boost sustainability through innovative and high-quality biologics solutions.”

The commitment of WuXi Biologics to sustainable development has been acknowledged by various leading global ESG rating agencies over the years. Notable recognitions include MSCI AAA Ratings, EcoVadis Platinum Medal, a place in the Dow Jones Best-in-Class World Index, and having an